This study demonstrates that genomic complexity assessed by SNPs arrays and determined as the number of breakpoints can be used to predict the outcome of early stage luminal HER2-negative invasive breast carcinomas. This evidence concerns the gene ERBB2 and invasive breast carcinoma.